Human Immune Activation by an HSV-Vectored Vaccine

Simple item record
dc.contributor.authorPowers, Tre
dc.date.accessioned2021-08-13T14:53:39Z
dc.date.available2021-08-13T14:53:39Z
dc.date.created2020
dc.description2020 Celebration of Student Research and Creativity presentationen_US
dc.description.abstractWe developed herpes simplex virus (HSV)-vectored vaccines for hepatitis C virus (HCV). Vaccine-infected human immune cells demonstrated activation by upregulated expression of inflammatory cytokines and chemokines and by enhanced expression of cellular maturation markers. Expression of adhesion molecules and chemokine receptors were altered in a manner consistent with immune activation. The HSV backbone of the vaccine appeared to be the major source of immune activation. While the initial vaccine target was hepatitis C virus, genes from any other infectious virus, such as novel corona viruses, could be inserted into this vaccine vector to generate immunity to that agent.en_US
dc.description.urihttps://youtu.be/eFRppAlUAzIen_US
dc.identifier.urihttp://hdl.handle.net/11216/3908
dc.language.isoen_USen_US
dc.publisherNorthern Kentucky Universityen_US
dc.relation.ispartofseriesCelebration of Student Research and Creativity;2020
dc.subjectHepatitis C virusen_US
dc.subjectHerpes simplex virusen_US
dc.subjectVaccinesen_US
dc.titleHuman Immune Activation by an HSV-Vectored Vaccineen_US
dc.typePresentationen_US

Files

Collections

Student Research and Creativity